PBE News and Press, Invesco Dynamic Biotech & Genome From 11/18/20

The pharmaceutical market reached a value of US$1.25 trillion in 2019, according to Statista data , up from US$887 billion in 2010. By 2024, that value is is expected to increase further to an estimated US$1.59 billion. Experienced and novice investors alike may want to consider...

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus. Firms are forging ahead with testing, treatment and vaccine research and product development. Results of even the most promising treatments, however, are not yet clear cut....

By Wvan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group, and Wendy Lam, Ph.D., Portfolio Manager and Research Analyst, Franklin Biotechnology Discovery Fund Innovation has always been a key driver for the biotechnology industry. Even in the midst of the CO...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications. ACADIA is well prepared financially and has t...

Image Source Exchange Traded Funds, ETFs, play an important role in a modern portfolio. Perhaps the clearest benefit is that ETFs provide diversification, which reduces risk and can improve returns at the same time. However, not all ETFs are created equal. In fact, there are thousands o...

Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to start the year. This continues their impressive streak from 2019. But are the current tech valuations sustainable? In a recent mark...

By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...

Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...

It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...